Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338739 | 0.84 | FFAR1 (0.43) | ACP3GABBR2GABBR1FFAR1LMNA | |
| SCHEMBL2172115 | 0.78 | FFAR1 (0.43) | ACP3GABBR2GABBR1FFAR1LMNA | |
| SCHEMBL339717 | 0.76 | ACP3 (0.44) | ACP3LMNAPOLBSRC | |
| SCHEMBL3817936 | 0.76 | ACP3 (0.63) | ACP3LMNAPOLBSRC | |
| SCHEMBL2171520 | 0.76 | ACP3 (0.46) | ACP3GABBR2GABBR1FFAR1LMNA | |
| SCHEMBL2173719 | 0.76 | ACP3 (0.46) | ACP3GABBR2GABBR1FFAR1SRC | |
| SCHEMBL11297322 | 0.74 | ACP3 (0.61) | ACP3GABBR2GABBR1SRCCYP2C19 | |
| SCHEMBL2171241 | 0.73 | ACP3 (0.44) | ACP3GABBR2GABBR1FFAR1SRC | |
| SCHEMBL340396 | 0.73 | ACP3 (0.44) | ACP3LMNAPOLBSRCCYP2C19 | |
| Hydrogen Peroxide SCHEMBL8609521 | 0.73 | ACP3 (0.50) | ACP3LMNAPOLBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| EP-1832594-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT FINANCE BVI LTD (VG) | 2011-05-18 | — | — | EP | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832594-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | ACP3 3182/4885GABBR2 157/4885GABBR1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.